Rhoptry antigens as Toxoplasma gondii vaccine target.
- Author:
Masoud FOROUTAN
1
;
Fatemeh GHAFFARIFAR
;
Zohreh SHARIFI
;
Abdolhosein DALIMI
;
Ogholniaz JORJANI
Author Information
- Publication Type:Review
- Keywords: Toxoplasma gondii; Mice; Vaccines; Immunization; Adjuvant
- MeSH: Animals; Antigens, Surface; Apicomplexa; Cell Size; Epitopes; Humans; Immunization; Life Cycle Stages; Mice; Molecular Biology; Mothers; Parasites; Prognosis; Toxoplasma*; Toxoplasmosis; Vaccines; Vaccines, DNA; Vaccines, Synthetic; Zoonoses
- From:Clinical and Experimental Vaccine Research 2019;8(1):4-26
- CountryRepublic of Korea
- Language:English
- Abstract: Toxoplasmosis is a cosmopolitan zoonotic infection, caused by a unicellular protozoan parasite known as Toxoplasma gondii that belongs to the phylum Apicomplexa. It is estimated that over one-third of the world's population has been exposed and are latently infected with the parasite. In humans, toxoplasmosis is predominantly asymptomatic in immunocompetent persons, while among immunocompromised individuals may be cause severe and progressive complications with poor prognosis. Moreover, seronegative pregnant mothers are other risk groups for acquiring the infection. The life cycle of T. gondii is very complex, indicating the presence of a plurality of antigenic epitopes. Despite of great advances, recognize and construct novel vaccines for prevent and control of toxoplasmosis in both humans and animals is still remains a great challenge for researchers to select potential protein sequences as the ideal antigens. Notably, in several past years, constant efforts of researchers have made considerable advances to elucidate the different aspects of the cell and molecular biology of T. gondii mainly on microneme antigens, dense granule antigens, surface antigens, and rhoptry proteins (ROP). These attempts thereby provided great impetus to the present focus on vaccine development, according to the defined subcellular components of the parasite. Although, currently there is no commercial vaccine for use in humans. Among the main identified T. gondii antigens, ROPs appear as a putative vaccine candidate that are vital for invasion procedure as well as survival within host cells. Overall, it is estimated that they occupy about 1%–30% of the total parasite cell volume. In this review, we have summarized the recent progress of ROP-based vaccine development through various strategies from DNA vaccines, epitope or multi epitope-based vaccines, recombinant protein vaccines to vaccines based on live-attenuated vectors and prime-boost strategies in different mouse models.
